1IA
TOVX icon

1620 Investment Advisors’s Theriva Biologics TOVX Stock Holding History

1620 Investment Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-60
Closed -$3K – 131
2022
Q2 		$3K Hold
60
– – ﹤0.01% 124
2022
Q1 		$4K Buy
+60
New +$4.09K ﹤0.01% 124

Other funds holding TOVX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

1620 Investment Advisors's TOVX Position: Q3 2022 in Review

1620 Investment Advisors sold out of Theriva Biologics (TOVX) in Q3 2022, closing a stake of 60 shares — an estimated $3K sold.

1620 Investment Advisors first reported a position in TOVX in Q1 2022 and held it in 2 quarters. The position peaked at $4K in Q1 2022. 24 funds tracked by Wall St. Rank hold TOVX as of Q3 2022.

  • 1620 Investment Advisors reported no remaining Theriva Biologics position as of Q3 2022 after selling out during the quarter.
  • 1620 Investment Advisors sold 60 Theriva Biologics shares in Q3 2022, an estimated $3K.
  • 1620 Investment Advisors first reported a position in Theriva Biologics in Q1 2022 and held it in 2 quarters.
  • 1620 Investment Advisors's Theriva Biologics position peaked at $4K in Q1 2022.
  • 24 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2022.

Based on 1620 Investment Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.